Health Minister Danielius Naumovas announced that all medications currently covered under the compulsory health insurance fund (PSDF) will maintain reimbursement status through the end of July. Naumovas stated that this continuity of coverage represents positive news for numerous patients, granting them continued access to innovative and effective drugs. These treatments are designed to enhance the management of oncological diseases, improve the control of cholesterol levels, and generally boost the quality of life and recovery prospects for patients.
The announcement also detailed forthcoming additions to the national drug formulary, effective in September. The SAM (State Medicines Agency) confirmed the reimbursement of nine new drugs intended for the treatment of various forms of cancer. Furthermore, the expansion includes two new drugs aimed at managing heart and vascular diseases alongside lipid metabolism disorders.
An additional drug is slated for reimbursement for patients diagnosed with hereditary hypercholesterolemia. These additions underscore a commitment to advancing patient health outcomes through improved pharmaceutical access. By integrating these specialized drugs, the healthcare system aims to provide comprehensive care across several critical medical fields.
The sustained coverage and the addition of these specific medications are expected to significantly improve the overall health management options available to the public, particularly regarding chronic conditions like high cholesterol and complex diseases.
Topics: #drugs #health #cholesterol
